Exelixis, Inc. (EXEL) stock analysis

Healthcare · Biotechnology

From the 10-K filed 2026-02-10

Business type: Franchise

How it makes money

Exelixis earns revenues primarily by selling its flagship cancer drug cabozantinib and by collecting royalties from partner-marketed therapies.

Sales related to cabozantinib account for the majority of revenues, driven by its approval across multiple cancer indications including renal cell carcinoma, hepatocellular carcinoma, and thyroid cancers under the brand name CABOMETYX. Additional revenue streams include royalties from collaboration agreements for products such as COTELLIC, marketed with Genentech, and MINNEBRO, licensed to Daiichi Sankyo in Japan.

What protects it: the moat

Exelixis relies on regulatory approvals, proprietary formulations, and strategic partnerships to protect its market position.

Management asserts that its competitive edge stems from patent protections on its flagship molecule cabozantinib and its ongoing clinical development of next-generation assets like zanzalintinib. However, the company operates in a highly competitive biopharmaceutical landscape where rivals with greater capital resources and larger research facilities constantly develop alternative oncology therapies.

What growth costs

Exelixis reinvests its operating cash flows into extensive clinical trials, pipeline advancement, and the in-licensing of new oncology assets.

The company deploys capital to support both company-sponsored and externally sponsored clinical trials evaluating cabozantinib and its lead clinical asset, zanzalintinib. Additionally, it funds early-stage pipeline programs and selectively acquires or in-licenses investigational oncology assets from third parties.

What could damage it

A failure to maintain broad physician prescription rates or the emergence of superior competitor therapies could directly impair cabozantinib sales and corporate profitability.

Because cabozantinib accounts for the majority of revenues, any loss of market acceptance among physicians, patients, or healthcare payers due to rival therapies would reduce product revenues, forcing the company to reduce operating expenses or modify its business plans.

About Exelixis, Inc.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Other companies in Biotechnology